TG Therapeutics CEO to Participate in H.C. Wainwright Global Investment Conference.

TG Therapeutics announced that CEO Michael S. Weiss will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025. Weiss will be part of a fireside chat on September 8 at 10:30am ET, and a live webcast will be available on the company's website.

New York, Sept. 02, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) has announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled to take place in New York, NY from September 8 to 10, 2025. The fireside chat, featuring Weiss, is set for Monday, September 8, at 10:30 am ET. A live webcast of the event will be available on the company's website.

The H.C. Wainwright 27th Annual Global Investment Conference is a prominent event that brings together leading investment professionals, analysts, and industry experts. Weiss's participation provides an opportunity for investors and financial professionals to gain insights into TG Therapeutics' strategic direction, recent developments, and future prospects.

TG Therapeutics is a fully integrated, commercial-stage biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell diseases. The company has received approvals from the U.S. Food and Drug Administration (FDA) and other regulatory bodies for its product BRIUMVI® (ublituximab-xiiy) for the treatment of multiple sclerosis and other related conditions.

For more information, visit the company's website at [www.tgtherapeutics.com](http://www.tgtherapeutics.com) or follow them on X (formerly Twitter) @TGTherapeutics and LinkedIn.

[1] https://www.stocktitan.net/news/TGTX/tg-therapeutics-to-participate-in-the-h-c-wainwright-27th-annual-lxro2ueup5py.html